The startup has developed a protein-based vaccine platform that utilizes a humanized monoclonal antibody fused with pathogen regions to target the CD40 molecule on dendritic cells. This technology enables the creation of vaccines for diseases such as HIV, SARS-CoV-2 variants, and human papillomavirus-related cancers, providing healthcare providers with effective treatment options.
Funding
$7.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current immunotherapies and vaccines often fail to generate targeted and effective immune responses, particularly in challenging diseases like cancer and infectious diseases. Existing treatments may lack the specificity needed to minimize side effects and maximize efficacy against the intended threat.
Solution
EnnoDC is a clinical-stage biotech company developing a novel class of immunotherapies called Dendritic Cell (DC) engagers. These Antibody Mediated Vaccines (AMVs) harness the power of both antibodies and vaccines by stimulating dendritic cells to deliver a more targeted and effective immune response. EnnoDC's technology platform uses a humanized anti-CD40 antibody to stimulate DCs, which are then directed to specific antigens from cancer cells or pathogens. This dual-action approach activates the immune system while guiding it towards a specific target, enhancing specificity and minimizing potential side effects.
Target Audience
EnnoDC's primary target audience includes patients with HPV16+ oropharyngeal cancer, prostate cancer, and infectious diseases, as well as healthcare providers seeking more effective and targeted immunotherapeutic options.
Features
- First-in-class antibody combining immunotherapy and vaccine benefits
- Humanized anti-CD40 antibody for stimulating dendritic cells (DCs)
- Antigen-specific targeting to direct immune response
- Development pipeline includes immunotherapies for HPV16+ oropharyngeal cancer (CD40.HVac), prostate cancer (CD40.PCA), and infectious diseases like COVID and HIV
- CD40.HVac is currently in Phase I/II clinical trials showing early signs of tumor regression, strong immunogenicity, and a favorable safety profile
- Demonstrated ability to induce HPV-specific CD4+ and CD8+ T cells
- AMV.PCA is designed to overcome immune evasion mechanisms in prostate cancer